PURPOSE OF REVIEW: The aim of this review is to describe the outcome of primary refractory diffuse large B cell lymphoma in the rituximab era and the different therapeutic options as well as new biological markers that could allow the pathologist to distinguish these cases at diagnosis. RECENT FINDINGS: Diffuse large B cell lymphoma outcome has been impressively improved since the introduction of rituximab in association with anthracycline-based chemotherapy; however, primary refractory patients still represent an unmet medical need. SUMMARY: If patients without relapse after 2 years from diagnosis have an outcome comparable to healthy individuals, primary refractory patients still represent 20% of the cases with a very poor overall survival. These cases are usually described as progressive patients during first line or patients reaching a nonadequate partial response or those relapsing within a year after reaching a response.
PURPOSE OF REVIEW: The aim of this review is to describe the outcome of primary refractory diffuse large B cell lymphoma in the rituximab era and the different therapeutic options as well as new biological markers that could allow the pathologist to distinguish these cases at diagnosis. RECENT FINDINGS: Diffuse large B cell lymphoma outcome has been impressively improved since the introduction of rituximab in association with anthracycline-based chemotherapy; however, primary refractory patients still represent an unmet medical need. SUMMARY: If patients without relapse after 2 years from diagnosis have an outcome comparable to healthy individuals, primary refractory patients still represent 20% of the cases with a very poor overall survival. These cases are usually described as progressive patients during first line or patients reaching a nonadequate partial response or those relapsing within a year after reaching a response.
Authors: Kelly M Trevino; Sarah C Rutherford; Chrystal Marte; Daniel Jie Ouyang; Peter Martin; Holly G Prigerson; John P Leonard Journal: J Palliat Med Date: 2019-10-18 Impact factor: 2.947
Authors: Umar Farooq; Matthew J Maurer; Carrie A Thompson; Gita Thanarajasingam; David J Inwards; Ivana Micallef; William Macon; Sergei Syrbu; Tasha Lin; Yi Lin; Stephen M Ansell; Grzegorz S Nowakowski; Thomas M Habermann; James R Cerhan; Brian K Link Journal: Br J Haematol Date: 2017-06-27 Impact factor: 6.998
Authors: Jeff Hosry; Parag Mahale; Francesco Turturro; Roberto N Miranda; Minas P Economides; Bruno P Granwehr; Harrys A Torres Journal: Int J Cancer Date: 2016-08-18 Impact factor: 7.396
Authors: Jeffrey W Craig; Michael J Mina; Jennifer L Crombie; Ann S LaCasce; David M Weinstock; Geraldine S Pinkus; Olga Pozdnyakova Journal: PLoS One Date: 2018-07-18 Impact factor: 3.240